1DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial[J ]. Lancet, 2006,368 ( 9549 ) : 1096-1105.
2Kahn SE,Haffner SM,Heise MA,et al. ADOPT study group. Glyeemic durability of rosiglitazone, metformin, or glyburide monotherapy[J]. N Engl J Med, 2006,355 (23): 2427-2443.
3Calkin AC, Forbes JM, Smith CM, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects[J]. Arterioscler Thromb Vasc Biol,2005,25(9) : 1903-1909.
4Mazzone T, Meyer P. M, Feinstein S. B, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial [J]. JAMA, 2006,296(21) : 2572-2581.
5Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone. Atherosclerosis Study [J]. J Intern Med,2007,261(3) :293-305.
6Howard G, O'Leary DH, Zaccaro D, et at. Insulin sensitivity and athrosclerosis[J]. Circulation, 1996,93 (10) : 1809-1817.
7Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of piogitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial[J]. JAMA, 2008,299 (13) :1561-1573.
8Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events ): a randomized controlled trial[J]. Lancet, 2005. 366 (9493). 1279-1289.
9Lincoff AM,Wolski K, Nicholls SJ,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus:ameta analysis of randomized trials[J].JAMA,2007, 298(10):1180-1188.
10McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents [ J ]. Pharmacoepidemiol Drug Saf, 2007,16(7) : 711-725.
